CD274 and cancer: Further studies have shown that the difference in the prognosis of patients with cancer receiving anti-PD-1/PD-L1 therapy is related to PD-L1 expression at cancer sites, and the benefit of immunotherapy is more obvious in patients with high PD-L1 expression than in those without 10, 11.